SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vivus, Why the Slide?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DDS-OMS who wrote (3062)8/18/1997 4:44:00 PM
From: Richard Singer   of 3991
 
Gary-

<<Speaking of news, will UK approval affect VVUS's price significantly, in
light of no flow through to the bottom line because they cant meet
present demand anyway? >>

I believe that if UK approval came tomorrow, it could probably move the stock back to, but not through, 28-30. This delay has made some longs nervous, and probably gotten rid of a bunch of the weaker ones.
And without the progress payment, Q3 will be less likely to provide a third straight blowout.

This deal is supposed to be next to done. So it would be unreasonable to expect much more than a retracement back to highs, if that, on this news. After all, two great earnings blowouts haven't been able to get us past the low 30's.

I agree with Rubble's expectation of more strength in anticipation of Q3, but that's still the better part of two months away. And if we get the earnings I'm expecting, the 30's might be a thing of the past by late September. Watch the backlog numbers---that, along with the progress payment, is the key to Q3 blowout. If they never catch up with that backlog(this quarter) I will be a happy (sh) long.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext